Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prodigy CAR-T CD19 in refractory systemic lupus erythematosus
TCTR20261006010Phase 2Recruiting
- Sponsor
- Chulalongkorn University Cancer Immunotherapy Fund
- Start
- Sep 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in systemic lupus erythematosus (SLE), sponsored by Chulalongkorn University Cancer Immunotherapy Fund. Primary endpoint: Safety of CD19 CAR T-cells. Started Sep 2026; status: recruiting.
02
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on TCTR20261006010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20261006010.